Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics


Pacira BioSciences, Inc. (PCRX): $48.25

0.56 (+1.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PCRX POWR Grades

  • Growth is the dimension where PCRX ranks best; there it ranks ahead of 80.44% of US stocks.
  • The strongest trend for PCRX is in Quality, which has been heading up over the past 179 days.
  • PCRX ranks lowest in Sentiment; there it ranks in the 6th percentile.

PCRX Stock Summary

  • With a price/earnings ratio of 107.49, PACIRA BIOSCIENCES INC P/E ratio is greater than that of about 95.79% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of 48.16%, PACIRA BIOSCIENCES INC's debt growth rate surpasses 79.66% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, PACIRA BIOSCIENCES INC is reporting a growth rate of -37.76%; that's higher than 27.47% of US stocks.
  • Stocks that are quantitatively similar to PCRX, based on their financial statements, market capitalization, and price volatility, are ATY, ROVR, STAA, OSS, and PAYC.
  • PCRX's SEC filings can be seen here. And to visit PACIRA BIOSCIENCES INC's official web site, go to www.pacira.com.

PCRX Valuation Summary

  • PCRX's price/earnings ratio is 109.2; this is 370.69% higher than that of the median Healthcare stock.
  • PCRX's EV/EBIT ratio has moved up 51.7 over the prior 144 months.

Below are key valuation metrics over time for PCRX.

Stock Date P/S P/B P/E EV/EBIT
PCRX 2022-11-25 3.5 3.0 109.2 46.4
PCRX 2022-11-23 3.4 2.9 107.6 45.8
PCRX 2022-11-22 3.4 2.9 106.1 45.4
PCRX 2022-11-21 3.4 2.9 107.2 45.7
PCRX 2022-11-18 3.4 2.9 107.8 45.9
PCRX 2022-11-17 3.3 2.8 104.4 44.8

PCRX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 5.45%.
  • Its 5 year net income to common stockholders growth rate is now at 99.77%.
  • Its year over year net income to common stockholders growth rate is now at -73.98%.
Over the past 15 months, PCRX's revenue has gone up $150,987,000.

The table below shows PCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 654.062 126.452 20.881
2022-06-30 614.318 144.085 39.234
2022-03-31 580.497 144.413 38.439
2021-12-31 541.533 125.717 41.98
2021-09-30 513.313 149.169 61.625
2021-06-30 503.075 128.663 174.084

PCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PCRX has a Quality Grade of C, ranking ahead of 72.8% of graded US stocks.
  • PCRX's asset turnover comes in at 0.394 -- ranking 116th of 681 Pharmaceutical Products stocks.
  • BCDA, NVAX, and RDHL are the stocks whose asset turnover ratios are most correlated with PCRX.

The table below shows PCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.394 0.738 0.064
2021-03-31 0.381 0.731 0.042
2020-12-31 0.411 0.727 0.042
2020-09-30 0.451 0.729 0.029
2020-06-30 0.491 0.740 0.018
2020-03-31 0.536 0.749 0.030

PCRX Price Target

For more insight on analysts targets of PCRX, see our PCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.00 Average Broker Recommendation 1.5 (Moderate Buy)

PCRX Stock Price Chart Interactive Chart >

Price chart for PCRX

PCRX Price/Volume Stats

Current price $48.25 52-week high $82.16
Prev. close $47.69 52-week low $46.03
Day low $46.88 Volume 533,998
Day high $48.33 Avg. volume 464,344
50-day MA $52.10 Dividend yield N/A
200-day MA $60.26 Market Cap 2.21B

Pacira BioSciences, Inc. (PCRX) Company Bio


Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.


PCRX Latest News Stream


Event/Time News Detail
Loading, please wait...

PCRX Latest Social Stream


Loading social stream, please wait...

View Full PCRX Social Stream

Latest PCRX News From Around the Web

Below are the latest news stories about PACIRA BIOSCIENCES INC that investors may wish to consider to help them evaluate PCRX as an investment opportunity.

Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?

Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.

Yahoo | November 18, 2022

New Research Reveals Common Treatments for Knee Pain are Falling Short, Placing Physical, Social, and Mental Burden on Patients

Nearly one in four adults in the United States suffers from chronic knee pain. New research shows the impact is widespread, causing physical, social, and mental burdens for patients on a daily basis, while also revealing that more Americans are living for years without adequate pain relief.

Yahoo | November 17, 2022

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022

-- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 -- TAMPA, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $54.9 million for the month of October 2022. The company’s net product sales include EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone ac

Yahoo | November 14, 2022

Pacira BioSciences Third Quarter 2022 Earnings: EPS Misses Expectations

Pacira BioSciences ( NASDAQ:PCRX ) Third Quarter 2022 Results Key Financial Results Revenue: US$167.5m (up 31% from 3Q...

Yahoo | November 9, 2022

Pacira BioSciences to Present at Two Healthcare Conferences in November

TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 15th at 8:00AM GMT (3:00AM ET).34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29th at 2:30PM ET. Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.c

Yahoo | November 8, 2022

Read More 'PCRX' Stories Here

PCRX Price Returns

1-mo -6.78%
3-mo -7.67%
6-mo -24.97%
1-year -8.30%
3-year 4.39%
5-year 6.63%
YTD -19.81%
2021 0.55%
2020 32.10%
2019 5.30%
2018 -5.76%
2017 41.33%

Continue Researching PCRX

Want to see what other sources are saying about Pacira BioSciences Inc's financials and stock price? Try the links below:

Pacira BioSciences Inc (PCRX) Stock Price | Nasdaq
Pacira BioSciences Inc (PCRX) Stock Quote, History and News - Yahoo Finance
Pacira BioSciences Inc (PCRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9383 seconds.